Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
Jing He(Gansu University of Traditional Chinese Medicine), Zhanguo Li(Shandong University of Science and Technology), Yew Ann Leong(Discovery Institute), Chuanhui Xu(Peking University), Eric F. Morand(Novartis (Switzerland)), Yuan An(Shanghai Jiao Tong University), Di Yu(East China Jiaotong University), Yunbo Wei(Qilu University of Technology), Jun Deng(Renji Hospital), Limin Ren(Peking University), Zhaohua Hou(Shandong University), Xiaolin Sun(Guangzhou University of Chinese Medicine), Yuzhou Gan(Peking University), Yuebo Jin(Peking University), Jianping Guo(Peking University), Shi Chen(Peking University), Chun Li(Peking University), Xia Zhang(Peking University), Lei Zhu(Peking University), Yuhui Li(University of Manchester), Yaping Chen(Melbourne Centre for Nanofabrication), Yin Su(Peking University), Jia Yuan(Peking University), Xin Hu(Discovery Institute), Rulin Jia(Peking University), Hua Ye(Ganzhou People's Hospital), Ru Li(Peking University), Xu Liu(Peking University), Haihong Yao(Peking University), Jinhong Feng(Qilu University of Technology), Xuewu Zhang(Peking University), Nan Shen(China-Japan Friendship Hospital)
Cited by 570
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478